Sarepta Therapeutics (NASDAQ:SRPT), a biotechnology company specializing in precision genetic medicines for rare diseases with a market capitalization of $11.2 billion, stands at a critical juncture ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at Needham ...

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Sarepta Therapeutics (SRPT – Research Report). The ...

In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), ...

Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...

Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement ...

Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene ...

Securities maintained their positive outlook on Sarepta Therapeutics (NASDAQ:SRPT), reiterating an Outperform rating and a ...

Sarepta Therapeutics unveiled new results from the second part of a clinical trial for its Duchenne muscular dystrophy gene ...

The gene therapy delandistrogene moxeparvovec-rokl showed clinically meaningful benefits and disease stabilization at 2 years ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $151.64, a high estimate of ...

While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...